Roth Capital Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to “Strong-Buy”

Roth Capital upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.

A number of other research analysts have also weighed in on TLSI. Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective for the company. Roth Mkm began coverage on TriSalus Life Sciences in a report on Monday. They set a “buy” rating and a $11.00 price target for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.25.

TriSalus Life Sciences Stock Up 5.9 %

NASDAQ:TLSI opened at $4.48 on Monday. The firm has a market capitalization of $136.60 million, a P/E ratio of -1.79 and a beta of 0.49. The company has a fifty day moving average of $4.40 and a 200 day moving average of $5.90. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $7.36 million during the quarter. As a group, analysts anticipate that TriSalus Life Sciences will post -1.51 EPS for the current year.

Insider Transactions at TriSalus Life Sciences

In other news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 32.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $240,000. Highbridge Capital Management LLC purchased a new position in TriSalus Life Sciences during the 2nd quarter worth $1,184,000. Finally, Duquesne Family Office LLC grew its holdings in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares in the last quarter. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.